Naval Daver, MD - Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management

Go online to PeerView.com/PYA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Newer treatment modalities for acute myeloid leukemia (AML) have rapidly eclipsed the decades-long cytarabine-based standard of care and helped clinicians adopt more personalized management using innovative cytotoxic platforms, targeted agents (including FLT3, BCL2, and IDH inhibitors), and other unique management strategies. Clinicians can now improve patient outcomes across all AML treatment settings, while at the same time selecting the most potent, personalized option that can be designed to address a given patient’s needs. This “Seminars and Tumor Board” activity, adapted from our recent live event held at the 2023 ASCO Annual Meeting and developed in collaboration with the HealthTree Foundation for Acute Myeloid Leukemia, reveals how modern baseline assessment paired with cutting-edge prognostication has pushed patient management to new heights of innovation and changed the management of patients with AML with therapeutically relevant features (such as FLT3 or IDH mutations), patients presenting without driver mutations, or individuals with comorbid illnesses or higher-risk features. Join the AML experts for a real-world “Tumor Board”–style discussion of how the latest evidence can inform your practice. Upon completion of this activity, participants should be better able to: Summarize baseline patient-related and disease-related factors, including age, comorbidities, functional status, and cytogenetic/mutational findings, that can influence prognostication and treatment selection in AML; Cite current evidence supporting the personalized use of novel treatment modalities, including new cytotoxic platforms, targeted agents, immunotherapy, and epigenetic strategies, for the management of newly diagnosed or relapsed/refractory AML; Integrate novel therapeutics into the personalized team-based management of AML according to the results of baseline assessment, presence or absence of targetable mutations, functional status, or AML subtype; and Address care delivery considerations, including optimized dosing and safety management, when caring for patients with AML